[
  {
    "title": "益方生物(688382.SH)：拟推553.4115万股的2022年限制性股票激励计划",
    "href": "http://stock.jrj.com.cn/2022/12/23221637235581.shtml",
    "datetime": "2022-12-23 22:16:37",
    "code": "688382"
  },
  {
    "title": "益方生物(688382.SH)：第三季度净亏损1.598亿元",
    "href": "http://stock.jrj.com.cn/2022/10/26172737086157.shtml",
    "datetime": "2022-10-26 17:27:25",
    "code": "688382"
  },
  {
    "title": "益方生物(688382.SH)：拟使用不超10亿元暂时闲置募集资金进行现金管理",
    "href": "http://stock.jrj.com.cn/2022/09/05162136973909.shtml",
    "datetime": "2022-09-05 16:21:16",
    "code": "688382"
  },
  {
    "title": "益方生物(688382.SH)：KRASG12C抑制剂D-1553的临床研究成果入选2022年世界肺癌大会(WCLC2022)报告",
    "href": "http://stock.jrj.com.cn/2022/08/07171836876205.shtml",
    "datetime": "2022-08-07 17:18:30",
    "code": "688382"
  },
  {
    "title": "益方生物(688382)：将于2022年7月25日在上交所科创板上市",
    "href": "http://stock.jrj.com.cn/2022/07/22101236834798.shtml",
    "datetime": "2022-07-22 10:12:27",
    "code": "688382"
  },
  {
    "title": "益方生物(688382.SH)：将于7月25日在科创板上市",
    "href": "http://stock.jrj.com.cn/2022/07/21191036832963.shtml",
    "datetime": "2022-07-21 19:10:13",
    "code": "688382"
  },
  {
    "title": "益方生物(688382.SH)披露发行结果：遭弃购91.1388万股、由主承销商包销",
    "href": "http://stock.jrj.com.cn/2022/07/19191436826018.shtml",
    "datetime": "2022-07-19 19:14:46",
    "code": "688382"
  },
  {
    "title": "益方生物(688382.SH)IPO网上摇号中签结果出炉：中签号共5.321万个",
    "href": "http://stock.jrj.com.cn/2022/07/17154536818434.shtml",
    "datetime": "2022-07-17 15:45:19",
    "code": "688382"
  },
  {
    "title": "益方生物(688382.SH)IPO定价18.12元/股 7月14日开启申购",
    "href": "http://stock.jrj.com.cn/2022/07/12192336804412.shtml",
    "datetime": "2022-07-12 19:23:25",
    "code": "688382"
  },
  {
    "title": "益方生物(688382)：首发11500万股，询价日期为2022年7月11日周一",
    "href": "http://stock.jrj.com.cn/2022/07/06090136785882.shtml",
    "datetime": "2022-07-06 09:01:06",
    "code": "688382"
  },
  {
    "title": "三问益方生物IPO：股权虚假转让？专利纠纷或赔偿？亏损15.4亿元还无销售？",
    "href": "http://stock.jrj.com.cn/2022/05/07081436586353.shtml",
    "datetime": "2022-05-07 08:14:00",
    "code": "688382"
  },
  {
    "title": "益方生物通过注册：年亏10亿 三个联合创始人均为美国籍",
    "href": "http://stock.jrj.com.cn/ipo/2022/04/06213436264767.shtml",
    "datetime": "2022-04-06 21:34:50",
    "code": "688382"
  },
  {
    "title": "证监会同意云从科技、益方生物科创板IPO注册",
    "href": "http://stock.jrj.com.cn/ipo/2022/04/06191936263991.shtml",
    "datetime": "2022-04-06 19:19:42",
    "code": "688382"
  },
  {
    "title": "商业秘密纠纷潜在风险影响几何？益方生物答复上市委意见落实函",
    "href": "http://stock.jrj.com.cn/2022/02/08101134304812.shtml",
    "datetime": "2022-02-08 10:11:11",
    "code": "688382"
  },
  {
    "title": "商业秘密纠纷影响几何均被关注，益方生物暂缓审议二次科创板上会过会",
    "href": "http://stock.jrj.com.cn/2022/01/21093734181209.shtml",
    "datetime": "2022-01-21 09:37:56",
    "code": "688382"
  },
  {
    "title": "科创板上市委：益方生物首发获通过",
    "href": "http://stock.jrj.com.cn/2022/01/20181534179352.shtml",
    "datetime": "2022-01-20 18:15:23",
    "code": "688382"
  },
  {
    "title": "暂缓审议专场！中钢洛耐、益方生物齐迎二次科创板上会",
    "href": "http://stock.jrj.com.cn/2022/01/17110134163156.shtml",
    "datetime": "2022-01-17 11:01:01",
    "code": "688382"
  },
  {
    "title": "暂缓审议后迎来二次上会，益方生物科创板IPO再闯关能否成功？",
    "href": "http://stock.jrj.com.cn/2022/01/14114034157121.shtml",
    "datetime": "2022-01-14 11:40:04",
    "code": "688382"
  },
  {
    "title": "益方生物冲刺科创板IPO遭暂缓审议，会通新材再融资获准通过",
    "href": "http://stock.jrj.com.cn/2021/12/03095933958946.shtml",
    "datetime": "2021-12-03 09:59:58",
    "code": "688382"
  },
  {
    "title": "益方生物近年来营收为0元：四名高管薪酬1891万元被问询 参照对象疑似可比性不高",
    "href": "http://stock.jrj.com.cn/2021/12/01175033950581.shtml",
    "datetime": "2021-12-01 17:50:07",
    "code": "688382"
  },
  {
    "title": "益方生物、井松智能、安达智能科创板IPO将迎上会，一家业绩持续亏损",
    "href": "http://stock.jrj.com.cn/2021/11/26111733922817.shtml",
    "datetime": "2021-11-26 11:17:02",
    "code": "688382"
  },
  {
    "title": "三轮问询后又回意见落实函，益方生物科创板IPO“长路漫漫”",
    "href": "http://stock.jrj.com.cn/2021/11/25094233917661.shtml",
    "datetime": "2021-11-25 09:42:56",
    "code": "688382"
  },
  {
    "title": "是否符合第五套上市标准相关要求？益方生物科创板IPO回复这样论证",
    "href": "http://stock.jrj.com.cn/2021/09/29093333534995.shtml",
    "datetime": "2021-09-29 09:33:03",
    "code": "688382"
  },
  {
    "title": "益方生物答科创板二轮问询，专利纠纷和商业秘密纠纷等被关注",
    "href": "http://stock.jrj.com.cn/2021/08/13090633246821.shtml",
    "datetime": "2021-08-13 09:06:10",
    "code": "688382"
  },
  {
    "title": "益方生物答科创板首轮27问：专利纠纷和商业秘密纠纷、红筹架构等被关注",
    "href": "http://stock.jrj.com.cn/2021/07/05142833047006.shtml",
    "datetime": "2021-07-05 14:28:55",
    "code": "688382"
  },
  {
    "title": "无核心产品、商业化盈利待解 益方生物冲刺科创板IPO现新进展",
    "href": "http://stock.jrj.com.cn/2021/05/08093432715445.shtml",
    "datetime": "2021-05-08 09:34:02",
    "code": "688382"
  },
  {
    "title": "创新药研发商益方生物启动上市 高瓴、启明、经纬等均为投资方",
    "href": "http://stock.jrj.com.cn/2020/12/19081731522940.shtml",
    "datetime": "2020-12-19 08:17:25",
    "code": "688382"
  },
  {
    "title": "[贝达药业]强强联合,贝达药业与益方生物携手推动创新药研发",
    "href": "http://stock.jrj.com.cn/2018/12/28000026821055.shtml",
    "datetime": "2018-12-28 00:00:00",
    "code": "688382"
  }
]